Steven Feldman to Health Care Costs
This is a "connection" page, showing publications Steven Feldman has written about Health Care Costs.
Connection Strength
7.348
-
Bashyam AM, Williford PM, Feldman SR. Safe Step Act: does it undermine step therapy? Dermatol Online J. 2020 Apr 15; 26(4).
Score: 0.649
-
Feldman SR, Zhang J, Martinez DJ, Lopez-Gonzalez L, Marchlewicz EH, Shrady G, Mendelsohn AM, Zhao Y. Real-world treatment patterns and healthcare costs of biologics and apremilast among patients with moderate-to-severe plaque psoriasis by metabolic condition status. J Dermatolog Treat. 2021 Mar; 32(2):203-211.
Score: 0.633
-
Feldman SR, Pelletier CL, Wilson KL, Mehta RK, Brouillette MA, Smith D, Bonafede MM. Real-world US healthcare costs of psoriasis for biologic-naive patients initiating apremilast or biologics. J Comp Eff Res. 2019 01; 8(1):45-54.
Score: 0.587
-
Feldman SR, Tian H, Gilloteau I, Mollon P, Shu M. Economic burden of comorbidities in psoriasis patients in the United States: results from a retrospective U.S. database. BMC Health Serv Res. 2017 05 08; 17(1):337.
Score: 0.529
-
Feldman SR, Levi E, Pathak P, Kakatkar S, Balkrishnan R. First-Line Fixed-Combination Psoriasis Treatment Is Associated With Lower Healthcare Costs. Skinmed. 2016; 14(4):266-272.
Score: 0.502
-
Feldman SR, Zhao Y, Shi L, Tran MH, Lu J. Economic and comorbidity burden among moderate-to-severe psoriasis patients with comorbid psoriatic arthritis. Arthritis Care Res (Hoboken). 2015 May; 67(5):708-17.
Score: 0.460
-
Feldman SR, Burudpakdee C, Gala S, Nanavaty M, Mallya UG. The economic burden of psoriasis: a systematic literature review. Expert Rev Pharmacoecon Outcomes Res. 2014 Oct; 14(5):685-705.
Score: 0.436
-
Ahn CS, Gustafson CJ, Sandoval LF, Davis SA, Feldman SR. Cost effectiveness of biologic therapies for plaque psoriasis. Am J Clin Dermatol. 2013 Aug; 14(4):315-26.
Score: 0.408
-
Feldman SR. Health reform in North Carolina: market hazard, moral imperative: why we need health reform. N C Med J. 2010 Jan-Feb; 71(1):101-2.
Score: 0.318
-
Feldman S, Pearce DJ, Williford PM. Surgical decision making for basal-cell carcinoma of the face. Lancet Oncol. 2008 Dec; 9(12):1119-20.
Score: 0.295
-
John Chen G, Yelverton CB, Polisetty SS, Housman TS, Williford PM, Teuschler HV, Feldman SR. Treatment patterns and cost of nonmelanoma skin cancer management. Dermatol Surg. 2006 Oct; 32(10):1266-71.
Score: 0.254
-
Balkrishnan R, Kulkarni AS, Cayce K, Feldman SR. Predictors of healthcare outcomes and costs related to medication use in patients with acne in the United States. Cutis. 2006 Apr; 77(4):251-5.
Score: 0.245
-
Pearce DJ, Nelson AA, Fleischer AB, Balkrishnan R, Feldman SR. The cost-effectiveness and cost of treatment failures associated with systemic psoriasis therapies. J Dermatolog Treat. 2006; 17(1):29-37.
Score: 0.241
-
Stein KR, Pearce DJ, Feldman SR. The impact of biologics on the quality of life of psoriasis patients and the economics of psoriasis care. Semin Cutan Med Surg. 2005 Mar; 24(1):52-7.
Score: 0.227
-
Pearce DJ, Thomas CG, Fleischer AB, Feldman SR. The cost of psoriasis therapies: considerations for therapy selection. Dermatol Nurs. 2004 Oct; 16(5):421-8, 432.
Score: 0.221
-
Aleshaki JS, Cardwell LA, Muse ME, Feldman SR. Adherence and resource use among psoriasis patients treated with biologics. Expert Rev Pharmacoecon Outcomes Res. 2018 12; 18(6):609-617.
Score: 0.145
-
Davis SA, Himmler S, Feldman SR. Cost-effectiveness analysis of using dermatologists versus pediatricians to treat mild to moderate acne. Dermatol Online J. 2017 May 15; 23(5).
Score: 0.133
-
Feldman SR, Zhao Y, Shi L, Tran MH. Economic and Comorbidity Burden Among Patients with Moderate-to-Severe Psoriasis. J Manag Care Spec Pharm. 2015 Oct; 21(10):874-88.
Score: 0.118
-
Patel P, Lin HC, Feldman SR, Fleischer AB, Nahata MC, Balkrishnan R. Medication choice and associated health care outcomes and costs for patients with acne and acne-related conditions in the United States. J Drugs Dermatol. 2011 Jul; 10(7):766-71.
Score: 0.088
-
Mudigonda T, Pearce DJ, Yentzer BA, Williford P, Feldman SR. The economic impact of non-melanoma skin cancer: a review. J Natl Compr Canc Netw. 2010 Aug; 8(8):888-96.
Score: 0.083
-
Balkrishnan R, Bhosle MJ, Fleischer AB, Feldman SR. Prior authorization for topical psoriasis treatments: is it cost-beneficial for managed care? J Dermatolog Treat. 2010 May; 21(3):178-84.
Score: 0.081
-
Nolan BV, Yentzer BA, Feldman SR. A review of home phototherapy for psoriasis. Dermatol Online J. 2010 Feb 15; 16(2):1.
Score: 0.080
-
Yentzer BA, Yelverton CB, Simpson GL, Simpson JF, Hwang W, Balkrishnan R, Feldman SR. Paradoxical effects of cost reduction measures in managed care systems for treatment of severe psoriasis. Dermatol Online J. 2009 Apr 15; 15(4):1.
Score: 0.076
-
Neidecker MV, Davis-Ajami ML, Balkrishnan R, Feldman SR. Pharmacoeconomic considerations in treating actinic keratosis. Pharmacoeconomics. 2009; 27(6):451-64.
Score: 0.074
-
Jayawant SS, Feldman SR, Camacho FT, Yentzer B, Balkrishnan R. Prescription refills and healthcare costs associated with topical metronidazole in Medicaid enrolled patients with rosacea. J Dermatolog Treat. 2008; 19(5):267-73.
Score: 0.069
-
Bhosle MJ, Feldman SR, Camacho FT, Timothy Whitmire J, Nahata MC, Balkrishnan R. Medication adherence and health care costs associated with biologics in Medicaid-enrolled patients with psoriasis. J Dermatolog Treat. 2006; 17(5):294-301.
Score: 0.060
-
Marchetti A, Feldman SR, Kimball AB, Anderson RR, Miller LH, Martin J, An P. Treatments for mild-to-moderate recalcitrant plaque psoriasis: expected clinical and economic outcomes for first-line and second-line care. Dermatol Online J. 2005 Mar 01; 11(1):1.
Score: 0.057
-
Kulkarni AS, Balkrishnan R, Richmond D, Pearce DJ, Feldman SR. Medication-related factors affecting health care outcomes and costs for patients with psoriasis in the United States. J Am Acad Dermatol. 2005 Jan; 52(1):27-31.
Score: 0.056
-
Kulkarni AS, Balkrishnan R, Camacho FT, Anderson RT, Feldman SR. Medication and health care service utilization related to depressive symptoms in older adults with psoriasis. J Drugs Dermatol. 2004 Nov-Dec; 3(6):661-6.
Score: 0.056
-
Housman TS, Williford PM, Feldman SR, Teuschler HV, Fleischer AB, Goldman ND, Balkrishnan R, Chen GJ. Nonmelanoma skin cancer: an episode of care management approach. Dermatol Surg. 2003 Jul; 29(7):700-11.
Score: 0.051
-
Dehkharghani S, Bible J, Chen JG, Feldman SR, Fleischer AB. The economic burden of skin disease in the United States. J Am Acad Dermatol. 2003 Apr; 48(4):592-9.
Score: 0.050
-
Martin E, Huang WW, Strowd LC, Hinkel VS, Feldman SR, Williford PM. Public Perception of Ethical Issues in Dermatology: Evidenced by New York Times Commenters. Dermatol Surg. 2018 12; 44(12):1571-1577.
Score: 0.037
-
Arcury TA, Vallejos QM, Feldman SR, Quandt SA. Treating skin disease: self-management behaviors of Latino farmworkers. J Agromedicine. 2006; 11(2):27-35.
Score: 0.015
-
Housman TS, Feldman SR, Williford PM, Fleischer AB, Goldman ND, Acostamadiedo JM, Chen GJ. Skin cancer is among the most costly of all cancers to treat for the Medicare population. J Am Acad Dermatol. 2003 Mar; 48(3):425-9.
Score: 0.012